Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications

Masci, Giovanna; Magagnoli, Massimo; Pedicini, Vittorio; Poretti, Dario; Castagna, Luca; Carnaghi, Carlo; Morenghi, Emanuela; Vecchio, Antonietta Del; Finotto, Rita; Brambilla, Giorgio; Santoro, Armando

doi:10.1007/s00520-006-0065-2

Cited by 8 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is no firm existing evidence regarding protection from BSI or site infections with use of a cuff . In our cohort, infections were not increased in individuals with noncuffed TSB‐CVCs.…”

Section: Discussioncontrasting

confidence: 52%

“…The presence of a cuff did not affect TSB‐CVC line failure outcomes in our study. Previously, the presence of a cuff in tunneled CVCs has been linked to less frequent accidental removal . Theoretically, the looping of the catheter should also be less common.…”

Section: Discussionmentioning

confidence: 99%

“…This evaluation may be limited by small sample size. Conversely, one important advantage to consider with noncuffed catheters is an easier, less invasive office based catheter removal …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluating safety of tunneled small bore central venous catheters in chronic kidney disease population: A quality improvement initiative

Bhutani

Ters

Kremers

et al. 2016

Hemodialysis International

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 52%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating safety of tunneled small bore central venous catheters in chronic kidney disease population: A quality improvement initiative

Bhutani

Ters

Kremers

et al. 2016

Hemodialysis International

View full text Add to dashboard Cite

show abstract

“…Nonimplanted devices may have a higher rate of accidental loss [13], and this may be expected to be the case for noncuffed devices inserted into upper limb veins, such as those in the current study. However, we did not observe CVC dislodgement in any of the studied CVCs, and these findings are consistent with a large study of oncology patients where durability was demonstrated when a similar device and insertion site were used [17].…”

Section: Discussionmentioning

confidence: 88%

Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices

Worth

Seymour

Slavin

2008

Support Care Cancer

View full text Add to dashboard Cite

Goals Central venous catheter (CVC)-related bloodstream infection (CR-BSI) is a significant complication in hematology patients. A range of CVC devices may be used, and risks for the development of complications are not uniform. The objectives of this study were to determine the natural history and rate of CVC-related complications and risk factors for CR-BSI and to compare device-specific complications in a hematology population. Patients and methods An observational cohort of patients with hematologic malignancy was prospectively studied following CVC insertion. Participants were reviewed until a CVC-related complication necessitated device removal, completion of therapy, death, or defined end-of-study date. The National Nosocomial Infection Surveillance definition for CR-BSI was used. Overall and device-specific rates of infective and noninfective complications were calculated and potential risk factors were captured.Main results One hundred six CVCs (75 peripherally inserted central venous catheters [PICCs], 31 nontunneled CVCs) were evaluated in 66 patients, over 2,399 CVC days. Thrombosis occurred in 16 cases (15.1%), exit-site infection in two (1.9%), and CR-BSI in 18 (7.5 per 1,000 CVC days). No significant differences were found when complication rates in PICC and nontunneled devices were compared. An underlying diagnosis of acute myeloid leukemia was negatively associated with CR-BSI (odds ratio (OR) 0.14, p=0.046), and a previous diagnosis of fungal infection was associated with infection (OR 22.82, p=0.031).Conclusions CR-BSI rates in our hematology population are comparable to prior reports. A low rate of exit-site infection and high proportion of thrombotic complications were observed. No significant differences in thrombotic or infective complications were evident when PICC and nontunneled devices were compared. PICC devices are a practical and safe option for management of hematology patients.

show abstract

“…16 A retrospective study assessing the safety and effectiveness of long-term, tunnelled, non-cuffed CVCs reported a CVC-related thrombosis incidence of 4.3%, most of which happened in patients with haematological malignancies (10 cases vs 3 cases with solid tumours). 17 A recent retrospective study reported an incidence of PICC-related symptomatic thrombosis of 0.15 per 1000 PICC-days. 18 Older studies have described that intraluminal thrombosis requiring catheter removal can occur at a frequency of 0.6-0.81 events per 1000 catheter-days.…”

Section: Retrospective Studiesmentioning

confidence: 99%

Central catheter-associated deep vein thrombosis in cancer: clinical course, prophylaxis, treatment

Marín

Bull

Kinzie

et al. 2021

BMJ Support Palliat Care

View full text Add to dashboard Cite

The adequate handling of central venous catheters is a key element in the management of patients with cancer. Catheter-associated deep vein thrombosis is frequently observed in patients with malignant diseases; however, despite being a common complication among these patients, objective information concerning its epidemiology, clinical course, prophylaxis and treatment strategies is very limited. The reported incidence of catheter-related thrombosis (CRT) is highly variable, depending on symptomatic events, or if patients are screened for asymptomatic thrombosis. Several factors have been identified as potential predisposing factors for CRT, both technical and pathological aspects. The anticoagulant of choice is still unclear; while low-molecular-weight heparin is most commonly used, recent studies assessing the role of direct oral anticoagulants in the treatment of CRT show promise as an alternative, but the evidence remains insufficient and the decision must be made on a case-by-case basis.

show abstract

Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications

Abstract: Vygon catheters do not seem to induce more early and late complications as compared with other more expensive devices, except for disadvantage of the high incidence rate of accidental losses.

Cited by 8 publications

References 17 publications

Evaluating safety of tunneled small bore central venous catheters in chronic kidney disease population: A quality improvement initiative

Evaluating safety of tunneled small bore central venous catheters in chronic kidney disease population: A quality improvement initiative

Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices

Central catheter-associated deep vein thrombosis in cancer: clinical course, prophylaxis, treatment

Contact Info

Product

Resources

About